GRADE 3A FOLLICULAR LYMPHOMA
Clinical trials for GRADE 3A FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new GRADE 3A FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for GRADE 3A FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for untreated lymphoma patients
Disease control CompletedThis study tested a combination of three targeted drugs (mosunetuzumab, polatuzumab vedotin, and obinutuzumab) in 42 people with untreated slow-growing B-cell non-Hodgkin lymphoma. The goal was to see how many patients achieved a complete response (no cancer detected). The drugs …
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 17, 2026 01:29 UTC
-
New combo therapy shows promise for lymphoma patients
Disease control CompletedThis study tested two different drug combinations in 135 people with untreated follicular lymphoma, a slow-growing blood cancer. One group received ofatumumab and bendamustine, while the other got those two drugs plus bortezomib. The goal was to see which combination led to more …
Matched conditions: GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC